Detail akcie Bio-Techne online

Business Summary: Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
Financial Summary: BRIEF: For the six months ended 31 December 2025, BIO-TECHNE Corp revenues decreased 1% to $582.4M. Net income applicable to common stockholders increased 11% to $76.2M. Revenues reflect Diagnostics and Genomics segment decrease of 4% to $160.6M, United States segment decrease of 7% to $301.8M, United Kingdom segment decrease of 1% to $26.9M. Net income reflects Corporate and Other segment loss decrease of 12% to $77.5M.